Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Acalabrutinib in Patients with Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Subjected to Allogeneic Hematopoietic Stem Cell Transplantation. a Phase 2 Study By the Polish Lymphoma Research Group

Sebastian Giebel, Anna Czyz, Iwona Hus, Lidia Gil, Krzysztof Giannopoulos, Joanna Romejko-Jarosinska, Maciej Majcherek, Agnieszka Szeremet, Anna Wache, Paulina Kwasnik, Wlodzimierz Mendrek, Wojciech Jurczak

Blood (2024) 144 (Supplement 1): 1660.

https://doi.org/10.1182/blood-2024-209931

Published: 2024

Journal Articles

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Blood (2024) 144 (Supplement 1): 970.

https://doi.org/10.1182/blood-2024-202365

Published: 2024

Journal Articles

Low Bone Mineral Content: A New Risk Factor for Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies

Anna Czyz, Diana Jedrzejuk, Paula Jablonowska, Maciej Majcherek, Agnieszka Szeremet, Bartlomiej Kuszczak, Magdalena Karasek, Marta Sobas, Tomasz Wrobel

Blood (2023) 142 (Supplement 1): 2149.

https://doi.org/10.1182/blood-2023-189524

Published: 2023

Journal Articles

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

Blood (2022) 140 (Supplement 1): 6241–6243.

https://doi.org/10.1182/blood-2022-156950

Published: 2022

Journal Articles

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Blood (2022) 140 (Supplement 1): 7747–7749.

https://doi.org/10.1182/blood-2022-167407

Published: 2022

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Blood (2022) 140 (Supplement 1): 9013–9015.

https://doi.org/10.1182/blood-2022-166184

Published: 2022

Journal Articles

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Blood (2021) 138 (26): 2753–2767.

https://doi.org/10.1182/blood.2021013626

Published: 2021

Includes: Supplemental data

Journal Articles

The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study

Blood (2021) 138 (Supplement 1): 3453.

https://doi.org/10.1182/blood-2021-153520

Published: 2021

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Agnieszka Wierzbowska, MDPhD, Agnieszka Pluta, MDPhD, Marta Antonina Libura, MDPhD, Anna Czyz, MDPhD, Sebastian Giebel, MDPhD, Piotr Stelmach, MDPhD, Magdalena Czemerska, MDPhD, Anna Kopinska, MD, Krzysztof Wozniczka, MDPhD, Grzegorz Helbig, MDPhD, Karol Wojcik, MD, Malgorzata Razny, MDPhD, Marta Sobas, MDPhD, Tomasz Wrobel, MDPhD, Andrzej Szczepaniak, MDPhD, Lidia Gil, MDPhD, Alicja Sadowska-Klasa, MD, Jan Zaucha, MDPhD, Tomasz Gromek, MDPhD, Marek Hus, MDPhD, Edyta Cichocka, MDPhD, Janusz Halka, MDPhD, Elzbieta Patkowska, Jolanta Wozniak, PhD, Agata Obara, MD, Beata Blajer-Olszewska, MD, Katarzyna Dulik, MD, Jerzy Holowiecki, MDPhD, Michal Soin, M.Sc., Tadeusz Robak, MDPhD, Nicole M. Cruz, MD, Nuria Mencia-Trinchant, PhD, Pinkal Desai, MDMPH, Sangmin Lee, MD, Michael B. Samuel, MD, Justin D. Kaner, MD, Ellen Ritchie, MD, Monica L. Guzman, PhD, Gail J. Roboz, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-140694

Published: 2020

Journal Articles

Improved Treatment Outcomes for Patients with Hodgkin Lymphoma Relapsing after Autologous Hematopoietic Stem Cell Transplantation in the Brentuximab Vedotin Era - the Real-Life Report from the Polish Lymphoma Research Group

Blood (2019) 134 (Supplement_1): 5276.

https://doi.org/10.1182/blood-2019-130484

Published: 2019

Journal Articles

Comparison of Myeloablative Conditioning Regimes Based on Either Busulfan or Total Body Irradiation in Combination with Fludarabine for Patients with Acute Myeloid Leukemia. a Study on Behalf of the Polish Adult Leukemia Group

Malgorzata Maria Sobczyk Kruszelnicka, MD, Anna Czyz, MD PhD, Anna Lojko-Dankowska, Magdalena Matuszak, Patrycja Mensah-Glanowska, MD PhD, Barbara Nasilowska-Adamska, Agnieszka Piekarska, Tomasz Czerw, Wlodzimierz Mendrek, Jacek Najda, Maria Sadus-Wojciechowska, Jerzy Holowiecki, Sebastian Giebel

Blood (2018) 132 (Supplement 1): 3391.

https://doi.org/10.1182/blood-2018-99-119073

Published: 2018

Journal Articles

Brentuximab Vedotin Alone and in Combination with Bendamustine As Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: Multicentre Experience of the Polish Lymphoma Research Group (PLRG)

Blood (2018) 132 (Supplement 1): 5375.

https://doi.org/10.1182/blood-2018-99-116610

Published: 2018

Journal Articles

Predictive and Prognostic Significance of Immunohistochemical Markers and Blood Absolute Lymphocyte Count in Diffuse Large B-Cell Lymphoma in Rituximab Era: A Polish Lymphoma Research Group (PLRG) Multicenter Retrospective Analysis

Anna Czyz, Monika Joks, Joanna E Drozd-Sokolowska, Wanda Knopinska-Posluszny, Magdalena Zawartko, Ewa Mizera-Nyczak, Dominik Dytfeld, Barbara Zdziarska, Wiktor-Wieslaw Jedrzejczak, Mieczyslaw Komarnicki

Blood (2014) 124 (21): 5413.

https://doi.org/10.1182/blood.V124.21.5413.5413

Published: 2014

Journal Articles

Role of Second Stem Cell Transplantation in Relapsed Lymphoproliferative Diseases: Remission Status Is the Most Important Factor Predicting the Outcome

Lidia Gil, MD PhD, Jan Styczynski, MD, PhD, Agnieszka Piekarska, MD PhD, Beata Jakubas, MD PhD, Katarzyna Drabko, MD PhD, Tomasz Wrobel, prof., Anna Czyz, MD PhD, Anna Lojko-Dankowska, MD PhD, Dominik Dytfeld, MD PhD, Adam Nowicki, MD, Patrycja Mensah-Glanowska, MD PhD, Wanda Knopinska-Posluszny, MD, PhD, Maria Bieniaszewska, MD PhD, Mariusz Wysocki, MD, PhD, Andrzej Hellmann, MD, PhD, Aleksander Skotnicki, Jerzy Kowalczyk, Kazimierz Kuliczkowski, MD PhD, prof., Mieczyslaw Komarnicki, MD PhD

Blood (2011) 118 (21): 3109.

https://doi.org/10.1182/blood.V118.21.3109.3109

Published: 2011

Journal Articles

Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with Individualized Protocol Adjusted to the Status of Minimal Residual Disease and Age. Interim Analysis of PALG ALL 5–2007 Study

Blood (2010) 116 (21): 2138.

https://doi.org/10.1182/blood.V116.21.2138.2138

Published: 2010

Journal Articles

Gemcitabine-Based Salvage Chemotherapy as a Bridge to Allogeneic Hematopoietic Stem Cell Transplantation for the Patients with Relapse of Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation.

Anna Czyz, Adam Nowicki, Lidia Gil, Dominik Dytfeld, Anna Lojko-Dankowska, Jan Styczynski, PhD, Mieczyslaw Komarnicki

Blood (2010) 116 (21): 2822.

https://doi.org/10.1182/blood.V116.21.2822.2822

Published: 2010

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation Following a Uniform Modified BEAM Conditioning Regimen for Hodgkin's Lymphoma – Prognostic Factors and Long-Term Outcomes.

Anna Czyz, Anna Lojko, Lidia Gil, Dominik Dytfeld, Danuta Drozdowska, Adam Nowicki, Maria Kozlowska, Krzysztof Sawinski, Jan Styczynski, Mieczyslaw Komarnicki

Blood (2009) 114 (22): 3406.

https://doi.org/10.1182/blood.V114.22.3406.3406

Published: 2009

Journal Articles

Palifermin Does Not Influence the Incidence and Severity of GvHD Nor Long-Term Survival of Patients with Hematological Diseases Undergoing HSCT

Blood (2008) 112 (11): 4301.

https://doi.org/10.1182/blood.V112.11.4301.4301

Published: 2008

Journal Articles

Minimal Residual Disease Status Is the Most Important Preditive Factor in Adults with Acute Lymphoblastic Leukemia. Prospective, Multicenter PALG 4-2002 MRD Study.

Jerzy Holowiecki, Malgorzata Krawczyk-Kulis, Sebastian Giebel, Krystyna Jagoda, Beata Stella-Holowiecka, Beata Jakubas, Monika Paluszewska, Ilona Seferynska, Anna Czyz, Wlodzimierz Mendrek, Aleksander Skotnicki, Wieslaw W. Jedrzejczak, Krzysztof Warzocha, Lech Konopka, Andrzej Hellmann

Blood (2007) 110 (11): 2821.

https://doi.org/10.1182/blood.V110.11.2821.2821

Published: 2007

Journal Articles

Clinical Outcome in Patients with AML Exhibiting Poor Mobilization of Progenitor Cells.

Wanda Knopinska-Posluszny, MD, PhD, Michal Taszner, MD, Jan M. Zaucha, MD, PHD, Lucja Kachel, MD, PHD, Anna Czyz, MD, PHD, Lidia Gil, MD, PHD, Jerzy Holowiecki, M. Komarnicki, Andrzej Hellmann

Blood (2006) 108 (11): 5439.

https://doi.org/10.1182/blood.V108.11.5439.5439

Published: 2006

NARROW

Acalabrutinib in Patients with Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Subjected to Allogeneic Hematopoietic Stem Cell Transplantation. a Phase 2 Study By the Polish Lymphoma Research Group

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Low Bone Mineral Content: A New Risk Factor for Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Improved Treatment Outcomes for Patients with Hodgkin Lymphoma Relapsing after Autologous Hematopoietic Stem Cell Transplantation in the Brentuximab Vedotin Era - the Real-Life Report from the Polish Lymphoma Research Group

Comparison of Myeloablative Conditioning Regimes Based on Either Busulfan or Total Body Irradiation in Combination with Fludarabine for Patients with Acute Myeloid Leukemia. a Study on Behalf of the Polish Adult Leukemia Group

Brentuximab Vedotin Alone and in Combination with Bendamustine As Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: Multicentre Experience of the Polish Lymphoma Research Group (PLRG)

Predictive and Prognostic Significance of Immunohistochemical Markers and Blood Absolute Lymphocyte Count in Diffuse Large B-Cell Lymphoma in Rituximab Era: A Polish Lymphoma Research Group (PLRG) Multicenter Retrospective Analysis

Role of Second Stem Cell Transplantation in Relapsed Lymphoproliferative Diseases: Remission Status Is the Most Important Factor Predicting the Outcome

Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with Individualized Protocol Adjusted to the Status of Minimal Residual Disease and Age. Interim Analysis of PALG ALL 5–2007 Study

Gemcitabine-Based Salvage Chemotherapy as a Bridge to Allogeneic Hematopoietic Stem Cell Transplantation for the Patients with Relapse of Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation.

Autologous Hematopoietic Stem Cell Transplantation Following a Uniform Modified BEAM Conditioning Regimen for Hodgkin's Lymphoma – Prognostic Factors and Long-Term Outcomes.

Palifermin Does Not Influence the Incidence and Severity of GvHD Nor Long-Term Survival of Patients with Hematological Diseases Undergoing HSCT

Minimal Residual Disease Status Is the Most Important Preditive Factor in Adults with Acute Lymphoblastic Leukemia. Prospective, Multicenter PALG 4-2002 MRD Study.

Clinical Outcome in Patients with AML Exhibiting Poor Mobilization of Progenitor Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only